返回 Agenda
Session 3: Late Phase and Post-Marketing Use Cases
Session Chair(s)
Camille Jackson
Director, Regulatory Policy; Legal and Regulatory
Flatiron Health , United States
Session 3: Late Phase and Post-Marketing Use Cases
Speaker(s)
Utilize Registry-based RCT to Improve Drug Development Efficiency: DAPA-MI as a Case Study
Jingyu (Julia) Luan, PhD
AstraZeneca, United States
Executive Regulatory Science Director, BioPharmaceuticals R&D
Implementing Clinical Trial Linkage to Real-World Data (RWD)
Mehdi Najafzadeh, PhD, MA, MS
Medidata AI, United States
Senior Director
Post-Approval Pregnancy Safety Study (PA-PSS) Innovations: New Ways for Studying the Safety of Medications During Pregnancy
Elsie Grace, PhD, MS
Eli Lilly and Company, United States
Senior Director, Global Patient Safety, Pharmacoepidemiology